11th Jan 2016 07:50
LONDON (Alliance News) - Pharmaceutical company Skyepharma PLC on Monday said its 2015 revenue will come in ahead of its previous expectations as it will book a milestone payment in the just-ended financial year.
The company said it will book a EUR10.0 million sales milestone payment from Mundipharma, its licensing partner for its Flutiform asthma treatment, in 2015, boosting the amount of revenue it will recognise for the year.
"Skyepharma has performed well in 2015 with robust growth of Flutiform and increasing contributions from Exparel and the GSK Ellipta products, which have resulted in significant revenue growth and cash generation. We have also made substantial progress with our pipeline," said Chief Executive Peter Grant.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
SKP.L